New Alkyne and Amine Linkers for Versatile Multiple Conjugation of OligonucleotidesShow others and affiliations
2021 (English)In: ACS Omega, E-ISSN 2470-1343, Vol. 6, no 1, p. 579-593Article in journal (Refereed) Published
Abstract [en]
Oligonucleotide (ON) conjugates are increasingly important tools for various molecular diagnostics, nanotechnological applications, and for the development of nucleic acid-based therapies. Multiple labeling of ONs can further equip ON-conjugates and provide improved or additional tailored properties. Typically, the preparation of ON multiconjugates involves additional synthetic steps and/or manipulations in post-ON assembly. This report describes the simplified methodology allowing for multiple labeling of ONs on a solid support and is compatible with phosphodiester as well as phosphorothioate (PS) ONs. The current approach utilizes two novel alkyne- A nd amino-functionalized linker phosphoramidites that can be readily synthesized from a common aminodiol intermediate in three steps. The combination of new linkers provides orthogonal functionalities, which allow for multiple attachments of similar or varied moieties. The linkers are incorporated into ONs during automated solid-phase ON synthesis, and the conjugation with functional entities is achieved by either amide bond formation or by copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC). The versatility of the approach is demonstrated by the synthesis of 5′-site ON multiconjugates with small molecules, peptides, and fatty acids as well as in the preparation of an internal peptide-ON conjugate.
Place, publisher, year, edition, pages
American Chemical Society , 2021. Vol. 6, no 1, p. 579-593
National Category
Natural Sciences
Identifiers
URN: urn:nbn:se:ri:diva-51930DOI: 10.1021/acsomega.0c05075Scopus ID: 2-s2.0-85099057868OAI: oai:DiVA.org:ri-51930DiVA, id: diva2:1520196
Note
Funding details: H2020 Marie Skłodowska-Curie Actions, MSCA, 721613; Funding details: Duchenne Parent Project, 17.013; Funding details: Vetenskapsrådet, VR, 2016-03283; Funding details: Muscular Dystrophy Association, MDA, MDA602835; Funding details: European Commission, EC; Funding text 1: The authors gratefully acknowledge funding from the Swedish Research Council (Grant No. 2016-03283), Duchenne Parent Project NL (Grant No. 17.013), Muscular Dystrophy Association (Grant No. MDA602835), and the European Commission: H2020 Marie Skłodowska-Curie Actions, “MMBIO” (Grant No. 721613).
2021-01-202021-01-202024-06-26Bibliographically approved